What it sells
Regulating the immune system to block cancer & autoimmune diseases
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma licensees/investors; eventual payers and prescribers if approved.
Workflow: what inputs become what output?
Lead program SFA-002 is an oral, once-daily deuterated short-chain fatty acid that resets immunity via the gut-immune axis; Phase 1b in 28 plaque psoriasis patients over 12 weeks, Phase 2 in preparation.
Economics: what it saves and how it charges
UnverifiedClinical-stage biotech with no product revenue; value rests on Phase 1b data (no treatment-emergent adverse events, 18 granted patents) and future licensing/partnering or approval.
Distribution: how it reaches customers
Investor and business inquiries by email; site directed at investors, healthcare professionals and the public.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.